- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | YD Bio plant Übernahme von Safe Save Medical in Taiwan für 26,9 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| Do | YD Bio to acquire Taiwan's SSMC for $26.87 million | 1 | Investing.com | ||
| 15.01. | YD Bio Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.01. | YD Bio Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 06.01. | YD Bio strebt Fusion mit Diagnostik-Spezialist EG BioMed an | 1 | Investing.com Deutsch | ||
| YD BIO Aktie jetzt für 0€ handeln | |||||
| 06.01. | YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal | 1 | Investing.com | ||
| 06.01. | YD Bio Limited: YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development | 219 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 05.01. | YD Bio advances cancer detection and eye disease platforms | 1 | Investing.com | ||
| 05.01. | YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap | 400 | GlobeNewswire (Europe) | Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 02.01. | YD Bio Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 16.12.25 | YD Bio plant Operationszentrum in Kalifornien für Diagnostik-Entwicklung | 1 | Investing.com Deutsch | ||
| 16.12.25 | YD Bio to establish California operations center for diagnostic development | 1 | Investing.com | ||
| 16.12.25 | YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center | 1 | GlobeNewswire (USA) | ||
| 09.12.25 | YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | YD Bio expands cancer detection platform to pancreatic and colorectal cancers | 2 | Investing.com | ||
| 02.12.25 | YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection | 2 | GlobeNewswire (USA) | ||
| 24.11.25 | FDA-Zulassung für Augenpflegeprodukte beflügelt YD Bio-Aktie | 1 | Investing.com Deutsch | ||
| 24.11.25 | YD Bio receives FDA clearance for contact lenses and artificial tears | 2 | Investing.com | ||
| 24.11.25 | YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics | 272 | GlobeNewswire (Europe) | Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited ("YD Bio" or the "Company") (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and... ► Artikel lesen | |
| 17.11.25 | YD Bio Ltd - 6-K, Report of foreign issuer | - | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,335 | -0,85 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 46 Euro belassen. 2025 sei ein weiteres durchwachsenes Jahr für den Medizintechnik-/Life-Sciences-Sektor... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,400 | 0,00 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 37,650 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) | - Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 69,98 | 0,00 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| IMMUNOVANT | 26,450 | +1,50 % | Immunovant Inc.: Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 | ||
| ALUMIS | 26,840 | 0,00 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 11,160 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| DYNE THERAPEUTICS | 17,880 | +1,02 % | Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? | ||
| STRUCTURE THERAPEUTICS | 87,15 | -2,13 % | Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It | ||
| IMMUNOME | 25,070 | 0,00 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ERASCA | 10,310 | +1,78 % | Erasca, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 72,56 | +0,14 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BIONTECH | 97,75 | +0,10 % | BERENBERG stuft Biontech auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Biontech auf "Buy" mit einem Kursziel von 155 US-Dollar belassen. 2025 sei ein weiteres durchwachsenes Jahr für den Medizintechnik-/Life-Sciences-Sektor... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,68 | +1,54 % | Piper Sandler raises Praxis Precision Medicines stock price target to $1,200 | ||
| RECURSION PHARMACEUTICALS | 4,320 | 0,00 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen |
Das Unternehmen YD BIO LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -1,060 (-8,71 %) liegt der Kurs bei 11,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu YD BIO LIMITED finden Sie auf Wallstreet Online.